RAS変異性白血病幹細胞は,ヴェネトクラックスに対する臨床耐性を引き起こす
Junya Sango1,2,3,4,5, Saul Carcamo1,2,3,4,5,6, Maria Sirenko7,8
1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nature
|October 31, 2024
まとめ
RAS変異は,急性骨髄性白血病 (AML) の後期的なイベントであり,以前の変異を必要とします. 変異したRASは特定の骨髄性原始細胞を変容させ,白血病幹細胞 (LSC) の階層と静脈クラックス耐性を影響する.
科学分野:
- 血液学
- 癌 生物学
- 分子腫瘍学
背景:
- RAS変異は,急性骨髄性白血病 (AML) の進行または再発の遅い段階で一貫して観察されています.
- AMLにおけるRAS変異の遅い獲得の生物学的な理由は不明である.
研究 の 目的:
- AMLにおけるRAS変異の強制的な遅い取得のメカニズム的根拠を調査する.
- RAS変異が白血病幹細胞 (LSC) の階層と治療応答にどのように影響するか解明する.
主な方法:
- ヒトの白血病発生モデルを用いて,突然変異の時間的な順序を研究した.
- 変異したRASの特定の造血元細胞の変容可能性を分析した.
- RAS変異型対RASワイルド型LSCにおけるBCL2ファミリーの遺伝子発現とヴェネトクラックス感受性を調べた.
主要な成果:
- RAS変異は,AMLにおいて,協力する変異に依存する,必須の遅いイベントです.
- 変異したRASは,以前に存在したドライバを持つ粒細胞-単細胞の祖先を特異的に変容させ,LSCの起源を変更します.
- RAS変異性LSCはBCL2ファミリーの遺伝子発現が変化し,ヴェネトクラックスに耐性を与え,治療の結果が悪い単細胞性AMLを引き起こす.
結論:
- RAS変異は,LSC標的細胞を制限することによって,AMLの非遺伝的細胞階層を形成します.
- RASによるLSCの変異は,AML患者のヴェネトクラックス耐性および単細胞再発に寄与する.
さらに関連する動画
関連する概念動画
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:40Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K